Kiniksa Pharmaceuticals (KNSA) Stock Rating Lowered by Zacks Investment Research

Kiniksa Pharmaceuticals (NASDAQ:KNSA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. “

A number of other analysts have also recently commented on the company. JMP Securities lifted their price target on Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, September 11th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $31.75.

Shares of KNSA stock opened at $19.94 on Thursday. Kiniksa Pharmaceuticals has a 1-year low of $13.04 and a 1-year high of $32.88.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Thursday, November 1st. The company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.03. Research analysts predict that Kiniksa Pharmaceuticals will post -2.63 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. American International Group Inc. acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at about $110,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at about $115,000. BlackRock Inc. acquired a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at about $173,000. Bank of New York Mellon Corp acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at about $435,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at about $348,000. 34.91% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Further Reading: What is a conference call?

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply